Drugs / rAd-p53
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials | ||||||
| Phase 2 | NCT02561546 | Dec 2015 → Oct 2017 | diabetes mellitus, hepatocellular carcinoma | Shenzhen SiBiono GeneTech Co.,Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT02429726 | Jun 2015 → Jun 2017 | pleural neoplasm | Shenzhen SiBiono GeneTech Co.,Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT02429037 | May 2015 → Dec 2018 | head and neck cancer | Shenzhen SiBiono GeneTech Co.,Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT02509169 | Oct 2014 → Dec 2016 | hepatocellular carcinoma | Shenzhen SiBiono GeneTech Co.,Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT02418988 | Jul 2014 → May 2017 | adult hepatocellular carcinoma | Shenzhen SiBiono GeneTech Co.,Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT01574729 | Aug 2012 → Aug 2015 | non-small cell lung carcinoma | Shenzhen SiBiono GeneTech Co.,Ltd | Unknown | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT00902083 | Jun 2009 → Jul 2012 | head and neck cancer | Shenzhen SiBiono GeneTech Co.,Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT00894153 | May 2009 → Jun 2012 | neoplasm | Shenzhen SiBiono GeneTech Co.,Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT00902122 | May 2009 → Aug 2012 | thyroid cancer | Shenzhen SiBiono GeneTech Co.,Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAd-p53 | “rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors” NCT00902083 ↗8“usingTAE plus recombinant adenoviral human p53 gene (rAd-p53)” NCT02509169 ↗ “local direct intra-tumor injection of rAd-p53 monotherapy” NCT00894153 ↗ “recombinant adenoviral human p53 gene (rAd-p53)” NCT02561546 ↗ |
| Known as | recombinant adenoviral human p53 gene | “recombinant adenoviral human p53 gene (rAd-p53)” NCT02561546 ↗ |
| Route | Other | “local direct intra-tumor injection” NCT00894153 ↗ |